Elsa Pan
About Elsa Pan
Elsa Pan is the Lead Oncology Solid Tumors, Commercial Regulatory Affairs at Bristol-Myers Squibb, with over 15 years of experience in strategic analysis, promotion compliance, and regulatory affairs.
Title at Bristol-Myers Squibb
Elsa Pan currently serves as the Lead Oncology Solid Tumors in Commercial Regulatory Affairs at Bristol-Myers Squibb. In her role, she oversees regulatory strategies and ensures compliance with promotional regulations. Her expertise in oncology, specifically in solid tumors, plays a crucial role in navigating the commercial landscape and fostering the development and marketing of oncology products.
Promotion Compliance Role
In addition to her leadership role, Elsa Pan also works as an Associate Director in Promotion Compliance at Bristol-Myers Squibb. She is responsible for monitoring promotional activities to ensure they adhere to regulatory standards. Her position involves meticulous oversight to maintain compliance with industry regulations and guidelines, further solidifying her comprehensive understanding of commercial regulatory affairs.
Career at Bristol-Myers Squibb
Elsa Pan has been with Bristol-Myers Squibb for over 15 years, starting as a Manager in Strategic Analysis and Intelligence from 2005 to 2009. She has since transitioned through various roles, including her current positions in oncology and promotion compliance. This long tenure at the company reflects her dedication and the depth of her expertise in the pharmaceutical industry.
Early Career as a Pharmacist
Before venturing into the pharmaceutical industry, Elsa Pan worked as a Staff Pharmacist at Pathmark Stores, Inc. from 2004 to 2006. This role provided her with a foundation in the healthcare sector, which she later built upon through her extensive career in strategic intelligence and regulatory affairs.
Education and Fellowship
Elsa Pan completed her Doctor of Pharmacy degree at Rutgers University from 1998 to 2004. Following her doctorate, she engaged in a post-doctoral fellowship in strategic intelligence through the Rutgers Pharmaceutical Industry Fellowship Program in collaboration with Bristol-Myers Squibb from 2004 to 2005. This fellowship marked the beginning of her long-term association with Bristol-Myers Squibb and set the stage for her subsequent roles in the company.